PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11529904-10	2001	Budesonide reduced eotaxin levels during repeat allergen challenge (P <0.05).	Budesonide	0-10	C-C motif chemokine ligand 11	Homo sapiens	19-26	
19571567-6	2009	METHODS: Following pretreatment of NHLF with tumor necrosis factor-alpha (TNF-alpha) in the presence of various concentrations of procaterol and/or budesonide, the eotaxin-stimulated eosinophil adhesion was determined using the peroxidase activity of eosinophils.	Budesonide	148-158	C-C motif chemokine ligand 11	Homo sapiens	164-171	
16266385-6	2005	A single dose of nasal budesonide caused a decrease in symptoms (P < 0.05) and nasal eosinophils (P < 0.05) with selective abrogation of IL-5 and IL-13 responses (P < 0.05), but a lack of effect on levels of eotaxin, RANTES, IL-8 and MCP-1.	Budesonide	23-33	C-C motif chemokine ligand 11	Homo sapiens	217-224	
11529904-12	2001	Topical budesonide attenuates this effect, suggesting the possibility that inhibitory effects on mucosal eotaxin may contribute to anti-eosinophilic actions of topical glucocorticosteroids.	Budesonide	8-18	C-C motif chemokine ligand 11	Homo sapiens	105-112	
10553092-2	1999	We investigated whether cytokines and the topical glucocorticoid budesonide differentially regulate RANTES, monocyte chemoattractant protein-4 (MCP-4), and eotaxin mRNA and protein expression in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells by Northern blot analysis and ELISAs.	Budesonide	65-75	C-C motif chemokine ligand 11	Homo sapiens	156-163	
11415942-3	2001	We found that IL-13 upregulated eotaxin messenger RNA and protein synthesis in the airway epithelial cell line BEAS-2B; this effect showed synergy with tumor necrosis factor (TNF)-alpha and also was inhibited by the glucocorticoid budesonide.	Budesonide	231-241	C-C motif chemokine ligand 11	Homo sapiens	32-39	
10553092-8	1999	Budesonide inhibited both RANTES- and eotaxin promoter-driven reporter gene activity.	Budesonide	0-10	C-C motif chemokine ligand 11	Homo sapiens	38-45	
10553092-9	1999	Budesonide also selectively accelerated the decay of eotaxin and MCP-4 mRNA.	Budesonide	0-10	C-C motif chemokine ligand 11	Homo sapiens	53-60	
10553092-7	1999	Although budesonide inhibited the expression of chemokine mRNA to a variable extent, it effectively inhibited production of eotaxin and RANTES protein.	Budesonide	9-19	C-C motif chemokine ligand 11	Homo sapiens	124-131	
32960007-11	2021	CONCLUSIONS: The treatment of salbutamol combined with budesonide for pediatric BA has significant therapeutic effects; it can restore the pulmonary functions rapidly and improve the immunity of the lung, reduce the levels of eotaxin, ECP and EOS of the child patients and promote EOS apoptosis.	Budesonide	55-65	C-C motif chemokine ligand 11	Homo sapiens	226-233